Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study - Curis (NASDAQ:CRIS)

Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib 

Related Keywords

,Curis Inc ,Aim Leukemia Phase ,Acute Myelogenous Leukemia ,Myelodysplastic Syndromes ,Takeaim Leukemia ,Takeaim Lymphoma ,